ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Physician Assistant

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,063Medicare Part D Prescriptions Filled, Including Refills

Rank: 13 out of 887

$434K Total Retail Price of All Prescriptions

Rank: 57 out of 887

312 Patients Receiving at Least One Drug in Part D
66%Patients 65 Years and Older
55% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in North Carolina
Lower avg

Schedule Two
Controlled Substances

4% of this provider’s 312 patients filled at least one prescription for a schedule two drug, compared to an average of 13%.

Schedule Three
Controlled Substances

28% of this provider’s 312 patients filled at least one prescription for a schedule three drug, compared to an average of 15%.

Risky Drugs to Seniors

1% of this provider’s 6,646 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 21%.

Prescription Price

$48 was the average price of a prescription from this provider, compared to $72 among peers.

Prescriptions per Patient

29 is the average number of prescriptions (including refills) per patient, compared to an average of 8.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in North Carolina
PRAVASTATIN SODIUM 460 356 1 12
OMEPRAZOLE 418 256 2 2
LOVASTATIN 400 286 3 58
AMLODIPINE BESYLATE 326 259 4 5
HYDROCODONE-ACETAMINOPHEN 295 221 S3 5 1
LISINOPRIL 285 243 6 4
METFORMIN HCL 278 206 7 8
LEVOTHYROXINE SODIUM 216 193 8 9
LISINOPRIL-HYDROCHLOROTHIAZIDE 193 139 9 22
FUROSEMIDE 162 118 10 7
ATENOLOL 160 148 11 37
FLUTICASONE PROPIONATE 158 109 12 29
GLIPIZIDE XL 130 125 13 106
METOPROLOL SUCCINATE 130 105 13 19
RANITIDINE HCL 126 84 15 59
TRAMADOL HCL 125 97 16 15
ATORVASTATIN CALCIUM 124 93 17 13
FENOFIBRATE 122 95 18 87
CITALOPRAM HBR 120 54 19 23
NEXIUM 103 82 20 18
ENALAPRIL MALEATE 99 77 21 103
MELOXICAM 95 83 22 28
ZOLPIDEM TARTRATE 94 75 23 14
CRESTOR 91 85 24 25
POTASSIUM CHLORIDE 90 64 25 21
HYDROCHLOROTHIAZIDE 89 71 26 10
SIMVASTATIN 88 83 27 3
ALLOPURINOL 83 65 28 66
AMLODIPINE BESYLATE-BENAZEPRIL 82 67 29 63
DIOVAN 79 58 30 81
PAROXETINE HCL 78 53 31 91
VENTOLIN HFA 77 43 32 89
CARVEDILOL 75 48 33 24
SPIRIVA 72 35 34 45
PREDNISONE 69 52 35 30
SYNTHROID 67 62 36 52
ALENDRONATE SODIUM 65 65 37 57
TAMSULOSIN HCL 60 50 38 38
METOPROLOL TARTRATE 56 30 39 16
DOXYCYCLINE HYCLATE 56 37 39 92
ATENOLOL-CHLORTHALIDONE 55 55 41 237
LANTUS SOLOSTAR 51 32 42 86
AMITRIPTYLINE HCL 51 18 R 42 70
LANTUS 51 40 42 97
KLOR-CON M20 50 48 45 127
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on June 10, 2009.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.